Corrigendum to “Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator.” (Journal of Affective Disorders (2018) 233 (92–99), (S0165032717308157), (10.1016/j.jad.2017.12.026));Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator

Journal of Affective Disorders

Volumn 233, Issue , 2018, Pages 92-99

  Machado Vieira, Rodrigo ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Biology; Biomarkers; Bipolar disorder; Depression; Lithium plasticity; Treatment

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; INOSITOL TRISPHOSPHATE; LITHIUM; NEUROTROPHIC FACTOR; PROTEIN BCL 2; PROTEIN KINASE B; ANTIDEPRESSANT AGENT; LITHIUM DERIVATIVE;

BIOLOGICAL MODEL; BIPOLAR DISORDER; BRAIN CHEMISTRY; BRAIN SIZE; CLINICAL OUTCOME; DRUG EFFECT; EPIGENETICS; EXCITOTOXICITY; HOMEOSTASIS; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; LITHIUM BLOOD LEVEL; MENTAL STRESS; MITOCHONDRIAL BIOGENESIS; MITOCHONDRION; NERVE CELL PLASTICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCHOLOGICAL RESILIENCE; PSYCHOPHARMACOTHERAPY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; BRAIN; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; BRAIN; HOMEOSTASIS; HUMANS; LITHIUM COMPOUNDS; NEURONAL PLASTICITY; NEURONS; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 85039966225     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2018.08.083     Document Type: Erratum

References (102)

1. Aldinger, F., Schulze, T.G., Environmental factors, life events, and trauma in the course of bipolar disorder. Psychiatry Clin. Neurosci. 71:1 (2017), 6–17.
2. Amsterdam, J.D., Shults, J., Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J. Clin. Psychopharmacol. 28 (2008), 171–181.
3. Amsterdam, J.D., Wang, C.H., Shwarz, M., Shults, J., Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial. J. Affect Disord. 112 (2009), 219–230.
4. Banerjee, U., Dasgupta, A., Rout, J.K., Singh, O.P., Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 37:1 (2012), 56–61.
5. Bauer, M., Adli, M., Ricken, R., Severus, E., Pilhatsch, M., Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 28:4 (2014), 331–342.
6. Benedetti, F., Serretti, A., Pontiggia, A., Bernasconi, A., Lorenzi, C., Colombo, C., Smeraldi, E., Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta −50 T/C SNP. Neurosci. Lett. 376:1 (2005), 51–55.
7. Beurel, E., Jope, R.S., Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl. Psychiatry, 4, 2014, e488.
8. Brambilla, P., Stanley, J.A., Sassi, R.B., Nicoletti, M.A., Mallinger, A.G., Keshavan, M.S., Soares, J.C., 1H MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsychopharmacology 29:10 (2004), 1918–1924.
9. Brambilla, P., Hatch, J.P., Soares, J.C., Limbic changes identified by imaging in bipolar patients. Curr. Psychiatry Rep. 10:6 (2008), 505–509.
10. Chen, W.T., Huang, T.L., Tsai, M.C., Bcl-2 associated with severity of manic symptoms in bipolar patients in a manic phase. Psychiatry Res. 225:3 (2015), 305–308.
11. Chuang, D.M., Lithium protection from glutamate excitotoxicity: therapeutic implications. Clin. Neurosci. Res. 4 (2004), 243–252.
12. Dager, S.R., Friedman, S.D., Parow, A., Demopoulos, C., Stoll, A.L., Lyoo, I.K., et al. Brain metabolic alterations in medication-free bipolar patients. Arch. Gen. Psychiatry 61 (2004), 450–458.
13. Davanzo, P., Thomas, M.A., Yue, K., Oshiro, T., Belin, T., Strober, M., McCracken, J., Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 24:4 (2001), 359–369.
14. de Sousa, R.T., Zanetti, M.V., Talib, L.L., Serpa, M.H., Chaim, T.M., Carvalho, A.F., Brunoni, A.R., Busatto, G.F., Gattaz, W.F., Machado-Vieira, R., Lithium increases platelet serine-9 phosphorylated GSK-3β levels in drug-free bipolar disorder during depressive episodes. J. Psychiatr. Res. 62 (2015), 78–83.
15. de Sousa, R.T., Streck, E.L., Zanetti, M.V., et al. Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. Psychopharmacology 232:1 (2015), 245–250.
16. de Sousa, R.T., van de Bilt, M.T., Diniz, B.S., Ladeira, R.B., Portela, L.V., Souza, D.O., Forlenza, O.V., Gattaz, W.F., Machado-Vieira, R., Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci. Lett. 494:1 (2011), 54–56.
17. de Sousa, R.T., Busnello, J.V., Forlenza, O.V., Zanetti, M.V., Soeiro-de-Souza, M.G., van de Bilt, M.T., Moreno, R.A., Zarate, C.A. Jr, Gattaz, W.F., Machado-Vieira, R., Early improvement of psychotic symptoms with lithium monotherapy as a predictor of later response in mania. J. Psychiatr. Res. 46:12 (2012), 1564–1568.
18. de Sousa, R.T., Machado-Vieira, R., Zarate, C.A. Jr, Manji, H.K., Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin. Ther. Targets 18:10 (2014), 1131–1147.
19. de Sousa, R.T., Zarate, C.A. Jr, Zanetti, M.V., Costa, A.C., Talib, L.L., Gattaz, W.F., Machado-Vieira, R., Oxidative stress in early stage bipolar disorder and the association with response to lithium. J. Psychiatr. Res. 50 (2014), 36–41.
20. de Sousa, R.T., Zanetti, M.V., Busatto, G.F., Mouro, M.G., Zarate, C.A. Jr, Gattaz, W.F., Higa, E.M., Machado-Vieira, R., Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes. J. Psychiatr. Res. 55 (2014), 96–100.
21. Diniz, B.S., Machado-Vieira, R., Forlenza, O.V., Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr. Dis. Treat. 9 (2013), 493–500.
22. Fitzgerald, P.J., Barkus, C., Feyder, M., Wiedholz, L.M., Chen, Y.C., Karlsson, R.M., Machado-Vieira, R., Graybeal, C., Sharp, T., Zarate, C., Harvey-White, J., Du, J., Sprengel, R., Gass, P., Bannerman, D., Holmes, A., Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?. Neurobiol. Dis. 40:3 (2010), 608–621.
23. Forester, B.P., Finn, C.T., Berlow, Y.A., Wardrop, M., Renshaw, P.F., Moore, C.M., Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study. Bipolar Disord. 10:6 (2008), 691–700.
24. Forlenza, O.V., de Paula, V.J., Machado-Vieira, R., Diniz, B.S., Gattaz, W.F., Does lithium prevent Alzheimer's disease?. Drugs Aging 29:5 (2012), 335–342.
25. Freland, L., Beaulieu, J.M., Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol. Neurosci., 20(5), 2012, 14.
26. Friedman, S.D., Dager, S.R., Parow, A., Hirashima, F., Demopulos, C., Stoll, A.L., Lyoo, I.K., Dunner, D.L., Renshaw, P.F., Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol. Psychiatry 56:5 (2004), 340–348.
27. Gelenberg, A.J., Kane, J.M., Keller, M.B., Lavori, P., Rosenbaum, J.F., Cole, K., Lavelle, J., Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N. Engl. J. Med. 321:22 (1989), 1489–1493.
28. Ghribi, O., Herman, M.M., Spaulding, N.K., Savory, J., Lithium inhibits aluminum-induced apoptosis in rabbit hippocampus, by preventing cytochrome c translocation, Bcl-2 decrease, Bax elevation and caspase-3 activation. J. Neurochem. 82 (2002), 137–145.
29. Gildengers, A.G., Butters, M.A., Aizenstein, H.J., Marron, M.M., Emanuel, J., Anderson, S.J., Weissfeld, L.A., Becker, J.T., Lopez, O.L., Mulsant, B.H., Reynolds, C.F. 3rd, Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder. Bipolar Disord. 17:3 (2015), 248–256.
30. Gray, J.D., McEwen, B.S., Lithium's role in neural plasticity and its implications for mood disorders. Acta Psychiatr. Scand. 128:5 (2013), 347–361.
31. Grof, P., Sixty years of lithium responders. Neuropsychobiology 62:1 (2010), 8–16.
32. Hajek, T., Bauer, M., Simhandl, C., Rybakowski, J., O'Donovan, C., Pfennig, A., König, B., Suwalska, A., Yucel, K., Uher, R., Young, L.T., MacQueen, G., Alda, M., Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol. Med. 44:3 (2014), 507–517.
33. Hammonds, M.D., Shim, S.S., Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin. Pharmacol. Toxicol. 105 (2009), 113–119.
34. Haroon, E., Fleischer, C.C., Felger, J.C., Chen, X., Woolwine, B.J., Patel, T., Hu, X.P., Miller, A.H., Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol. Psychiatry 21:10 (2016), 1351–1357.
35. Hashimoto, K., Koizumi, H., Nakazato, M., Shimizu, E., Iyo, M., Role of brain-derived neurotrophic factor in eating disorders: recent findings and its pathophysiological implications. Prog. Neuropsychopharmacol. Biol. Psychiatry 29:4 (2005), 499–504.
36. Hokin, L.E., Dixon, J.F., Los, G.V., A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices. Adv. Enzym. Regul. 36 (1996), 229–244.
37. Kapczinski, F., Frey, B.N., Kauer-Sant'Anna, M., Grassi-Oliveira, R., Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev. Neurother. 8:7 (2008), 1101–1113.
38. Kemp, D.E., Ganocy, S.J., Brecher, M., Carlson, B.X., Edwards, S., Eudicone, J.M., Evoniuk, G., Jansen, W., Leon, A.C., Minkwitz, M., Pikalov, A., Stassen, H.H., Szegedi, A., Tohen, M., Van Willigenburg, A.P., Calabrese, J.R., Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J. Affect Disord. 130:1–2 (2011), 171–179.
39. Kempton, M.J., Geddes, J.R., Ettinger, U., Williams, S.C., Grasby, P.M., Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch. Gen. Psychiatry 65:9 (2008), 1017–1032.
40. Kessing, L.V., Søndergård, L., Forman, J.L., Andersen, P.K., Lithium treatment and risk of dementia. Arch. Gen. Psychiatry 65:11 (2008), 1331–1335.
41. Kessing, L.V., Hellmund, G., Andersen, P.K., Predictors of excellent response to lithium: results from a nationwide register-based study. Int. Clin. Psychopharmacol. 26 (2011), 323–328.
42. Khairova, R., Pawar, R., Salvadore, G., Juruena, M.F., de Sousa, R.T., Soeiro-de-Souza, M.G., Salvador, M., Zarate, C.A., Gattaz, W.F., Machado-Vieira, R., Effects of lithium on oxidative stress parameters in healthy subjects. Mol. Med Rep. 5 (2012), 680–682.
43. Khairova, R.A., Machado-Vieira, R., Du, J., Manji, H.K., A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J. Neuropsychopharmacol. 12:4 (2009), 561–578.
44. Kim, H.-W., Rapoport, S.I., Rao, J.S., Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol. Dis. 37 (2010), 596–603.
45. Lazarewicz, J.W., Salińska, E., Role of calcium in glutamate-mediated toxicity: mechanisms of calcium fluxes in rabbit hippocampus in vivo investigated with microdialysis. Acta Neurobiol. Exp. 53 (1993), 3–13.
46. Liochev, S.I., Fridovich, I., The relative importance of HO* and ONOO- in mediating the toxicity of O*-. Free Radic. Biol. Med. 26:5–6 (1999), 777–778.
47. Lyoo, I.K., Dager, S.R., Kim, J.E., Yoon, S.J., Friedman, S.D., Dunner, D.L., Renshaw, P.F., Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacology 35:8 (2010), 1743–1750.
48. Machado-Vieira, R., Zanetti, M.V., Otaduy, M.C., De Sousa, R.T., Soeiro-de-Souza, M.G., Costa, A.C., Carvalho, A.F., Leite, C.C., Busatto, G.F., Zarate, C.A. Jr, Gattaz, W.F., Increased brain lactate during depressive episodes and reversal effects by lithium monotherapy in drug-naive bipolar disorder: a 3-T 1H-MRS Study. J. Clin. Psychopharmacol. 37:1 (2017), 40–45.
49. Machado-Vieira, R., Tracking the impact of translational research in psychiatry: state of the art and perspectives. J. Transl. Med., 10, 2012, 175.
50. Machado-Vieira, R., Tracking the impact of translational research in psychiatry: state of the art and perspectives. J. Transl. Med., 28(10), 2012, 175.
51. Machado-Vieira, R., Manji, H.K., Zarate, C.A., The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 11:Suppl 2 (2009), 92–109.
52. Machado-Vieira, R., Soeiro-De-Souza, M.G., Richards, E.M., Teixeira, A.L., Zarate, C.A., Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J. Biol. Psychiatry 15 (2014), 84–95.
53. Machado-Vieira, R., Zanetti, M.V., DE Sousa, R.T., Soeiro-DE-Souza, M.G., Moreno, R.A., Busatto, G.F., Gattaz, W.F., Lithium efficacy in bipolar depression with flexible dosing: a six-week, open-label, proof-of-concept study. Exp. Ther. Med. 8:4 (2014), 1205–1208.
54. Machado-Vieira, R., Luckenbaugh, D.A., Soeiro-de-Souza, M.G., Marca, G., Henter, I.D., Busnello, J.V., Gattaz, W.F., Zarate, C.A. Jr, Early improvement with lithium in classic mania and its association with later response. J. Affect. Disord. 144:1–2 (2013), 160–164.
55. Machado-Vieira, R., Otaduy, M.C., Zanetti, M.V., De Sousa, R.T., Dias, V.V., Leite, C.C., Forlenza, O.V., Busatto, G.F., Soares, J.C., Gattaz, W.F., A selective association between central and peripheral lithium levels in remitters in bipolar depression: a 3T-(7) Li magnetic resonance spectroscopy study. Acta Psychiatr. Scand. 133:3 (2016), 214–220.
56. Machado-Vieira, R., Andreazza, A.C., Viale, C.I., Zanatto, V., Cereser, V., da Silva Vargas, R., Kapczinski, F., Portela, L.V., Souza, D.O., Salvador, M., Gentil, V., Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 421 (2007), 33–36.
57. Machado-Vieira, R., Gattaz, W.F., Zanetti, M.V., De Sousa, R.T., Carvalho, A.F., Soeiro-de-Souza, M.G., Leite, C.C., Otaduy, M.C., A longitudinal (6-week) 3T (1)H-MRS study on the effects of lithium treatment on anterior cingulate cortex metabolites in bipolar depression. Eur. Neuropsychopharmacol. 25:12 (2015), 2311–2317.
58. Machado-Vieira, R., Pivovarova, N.B., Stanika, R.I., Yuan, P., Wang, Y., Zhou, R., et al. The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol. Psychiatry 69 (2011), 344–352.
59. Maj, M., The effect of lithium in bipolar disorder: a review of recent research evidence. Bipolar Disord. 5:3 (2003), 180–188.
60. Moore, G.J., Bebchuk, J.M., Hasanat, K., Chen, G., Seraji-Bozorgzad, N., Wilds, I.B., Faulk, M.W., Koch, S., Glitz, D.A., Jolkovsky, L., Manji, H.K., Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biol. Psychiatry 48:1 (2000), 1–8.
61. Moore, G.J., Bebchuk, J.M., Wilds, I.B., Chen, G., Manji, H.K., Lithium-induced increase in human brain grey matter. Lancet 356:9237 (2000), 1241–1242.
62. Moore, G.J., Cortese, B.M., Glitz, D.A., Zajac-Benitez, C., Quiroz, J.A., Uhde, T.W., Drevets, W.C., Manji, H.K., A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J. Clin. Psychiatry 70:5 (2009), 699–705.
63. Nassar, A., Azab, A.N., Effects of lithium on inflammation. ACS Chem. Neurosci. 5:6 (2014), 451–458.
64. Nierenberg, A.A., Friedman, E.S., Bowden, C.L., et al. Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am. J. Psychiatry 70 (2013), 102–110.
65. Nolen, W.A., Weisler, R.H., The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord. 15 (2013), 100–109.
66. Nonaka, S., Hough, C.J., Chuang, D.M., Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc. Natl. Acad. Sci. USA 95:5 (1998), 2642–2647.
67. Ozaki, N., Chuang, D.M., Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J. Neurochem. 69:6 (1997), 2336–2344.
68. Patel, N.C., DelBello, M.P., Cecil, K.M., Stanford, K.E., Adler, C.M., Strakowski, S.M., Temporal change in N-acetyl-aspartate concentrations in adolescents with bipolar depression treated with lithium. J. Child Adolesc. Psychopharmacol. 18:2 (2008), 132–139.
69. Perlis, R.H., Sachs, G.S., Lafer, B., et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am. J. Psychiatry 159 (2002), 1155–1159.
70. Phillips, M.L., Travis, M.J., Fagiolini, A., Kupfer, D.J., Medication effects in neuroimaging studies of bipolar disorder. Am. J. Psychiatry 165:3 (2008), 313–320.
71. Polidori, M.C., Frei, B., Cherubini, A., Nelles, G., Rordorf, G., Keaney, J.F., Schwamm, L., Mecocci, P., Koroshetz, W.J., Beal, M.F., Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radic. Biol. Med. 25 (1998), 561–567.
72. Quiroz, J.A., Machado-Vieira, R., Zarate, C.A. Jr, et al. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 62:1 (2010), 50–60.
73. Rybakowski, J.K., Suwalska, A., Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int. J. Neuropsychopharmacol. 13:5 (2010), 617–622.
74. Rybakowski, J.K., Factors associated with lithium efficacy in bipolar disorder. Harv. Rev. Psychiatry 22:6 (2014), 353–357.
75. Rybakowski, J.K., Response to lithium in bipolar disorder: clinical and genetic findings. ACS Chem. Neurosci. 5:6 (2014), 413–421.
76. Schäfer, M., Goodenough, S., Moosmann, B., Behl, C., Inhibition of glycogen synthase kinase 3 beta is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res 1005 (2004), 84–89.
77. Selek, S., Nicoletti, M., Zunta-Soares, G.B., Hatch, J.P., Nery, F.G., Matsuo, K., Sanches, M., Soares, J.C., A longitudinal study of fronto-limbic brain structures in patients with bipolar I disorder during lithium treatment. J. Affect Disord. 150:2 (2013), 629–633.
78. Severus, W.E., Kleindienst, N., Seemüller, F., et al. What is the optimal serum lithium level in the long-term treatment of bipolar disorder - a review?. Bipolar Disord. 10 (2008), 231–237.
79. Silverstone, P.H., McGrath, B.M., Kim, H., Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord. 7:1 (2005), 1–10.
80. Soeiro-de-Souza, M.G., Dias, V.V., Figueira, M.L., Forlenza, O.V., Gattaz, W.F., Zarate, C.A. Jr, Machado-Vieira, R., Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder. Acta Psychiatr. Scand. 126:5 (2012), 332–341.
81. Soeiro-de-Souza, M.G., Salvadore, G., Moreno, R.A., Otaduy, M.C., Chaim, K.T., Gattaz, W.F., Zarate, C.A. Jr, Machado-Vieira, R., Bcl-2rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. Neuropsychopharmacology 38:3 (2013), 468–475.
82. Soeiro-de-Souza, M.G., Gold, P.W., Brunoni, A.R., de Sousa, R.T., Zanetti, M.V., Carvalho, A.F., Gattaz, W.F., Machado-Vieira, R., Teixeira, A.L., Lithium decreases plasma adiponectin levels in bipolar depression. Neurosci. Lett. 564 (2014), 111–114.
83. Soeiro-de-Souza, M.G., Teixeira, A.L., Mateo, E.C., Zanetti, M.V., Rodrigues, F.G., de Paula, V.J., Bezerra, J.F., Moreno, R.A., Gattaz, W.F., Machado-Vieira, R., Leukocyte telomerase activity and antidepressant efficacy in bipolar disorder. Eur. Neuropsychopharmacol. 24:7 (2014), 1139–1143.
84. Sportiche, S., Geoffroy, P.A., Brichant-Petitjean, C., Gard, S., Khan, J.P., Azorin, J.M., Henry, C., Leboyer, M., Etain, B., Scott, J., Bellivier, F., Clinical factors associated with lithium response in bipolar disorders. Aust. N. Z. J. Psychiatry, 2016, 23.
85. Stork, C., Renshaw, P.F., Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry. 10 (2005), 900–919.
86. Sun, X., Wang, J.F., Tseng, M., Young, L.T., Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J. Psychiatry Neurosci. 31 (2006), 189–196.
87. Suppes, T., Marangell, L.B., Bernstein, I.H., et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J. Affect Disord. 111 (2008), 334–343.
88. Swann, A.C., Daniel, D.G., Kochan, L.D., Wozniak, P.J., Calabrese, J.R., Psychosis in mania: specificity of its role in severity and treatment response. J. Clin. Psychiatry 65:6 (2004), 825–829.
89. Tighe, S.K., Mahon, P.B., Potash, J.B., Predictors of lithium response in bipolar disorder. Ther. Adv. Chronic Dis. 2:3 (2011), 209–226.
90. Tobe, B.T.D., Crain, A.M., Winquist, A.M., Calabrese, B., Makihara, H., Zhao, W.N., et al. Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proc. Natl. Acad. Sci., 114, 2017 E4462 E4471 USA.
91. Toker, L., Bersudsky, Y., Plaschkes, I., Chalifa-Caspi, V., Berry, G.T., Buccafusca, R., Moechars, D., Belmaker, R.H., Agam, G., Inositol-related gene knockouts mimic lithium's effect on mitochondrial function. Neuropsychopharmacology 39:2 (2014), 319–328.
92. Valvassori, S.S., Rezin, G.T., Ferreira, C.L., Moretti, M., Gonçalves, C.L., Cardoso, M.R., Streck, E.L., Kapczinski, F., Quevedo, J., Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J. Psychiatr. Res. 44:14 (2010), 903–909.
93. Wasserman, M.J., Corson, T.W., Sibony, D., Cooke, R.G., Parikh, S.V., Pennefather, P.S., Li, P.P., Warsh, J.J., Chronic Lithium Treat. attenuates Intracell. Calcium mobilization: Neuropsychopharmacol. 29 (2004), 759–769.
94. Williams, R.S., Cheng, L., Mudge, A.W., Harwood, A.J., A common mechanism of action for three mood-stabilizing drugs. Nature 417:6886 (2002), 292–295.
95. Yatham, L.N., Kennedy, S.H., Parikh, S.V., Schaffer, A., Beaulieu, S., Alda, M., O'Donovan, C., Macqueen, G., McIntyre, R.S., Sharma, V., Ravindran, A., Young, L.T., Milev, R., Bond, D.J., Frey, B.N., Goldstein, B.I., Lafer, B., Birmaher, B., Ha, K., Nolen, W.A., Berk, M., Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 15:1 (2013), 1–44.
96. Yazlovitskaya, E.M., Edwards, E., Thotala, D., Fu, A., Osusky, K.L., Whetsell, W.O. Jr, Boone, B., Shinohara, E.T., Hallahan, D.E., Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res. 66:23 (2006), 11179–11186.
97. Yildiz, A., Demopulos, C.M., Moore, C.M., Renshaw, P.F., Sachs, G.S., Effect of lithium on phosphoinositide metabolism in human brain: a proton decoupled (31)P magnetic resonance spectroscopy study. Biol. Psychiatry 50:1 (2001), 3–7.
98. Young, A.H., McElroy, S.L., Bauer, M., et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J. Clin. Psychiatry 71 (2010), 150–162.
99. Yucel, K., McKinnon, M.C., Taylor, V.H., Macdonald, K., Alda, M., Young, L.T., MacQueen, G.M., Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology 195:3 (2007), 357–367.
100. Yuskaitis, C.J., Jope, R.S., Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell. Signal. 21 (2009), 264–273.
101. Zanetti, M.V., Otaduy, M.C., de Sousa, R.T., Gattaz, W.F., Busatto, G.F., Leite, C.C., Machado-Vieira, R., Bimodal effect of lithium plasma levels on hippocampal glutamate concentrations in bipolar II depression: a pilot study. Int J. Neuropsychopharmacol., 18(6), 2014.
102. Zarate, C.A. Jr, Machado-Vieira, R., GSK-3: a key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput. Bipolar Disord. 18:8 (2016), 702–705.